SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma Ltd has received tentative approval for Tenofovir Disoproxil Fumarate tablets in 300 mg dosage from the US Food & Drug Administration (USFDA). It is the generic equivalent of Gilead Sciences Inc. Viread tablets 300 mg and falls under the Anti-Retroviral (ARV) segment.

 

The drug is indicated in combination with other ARVs for the treatment of HIV-I infection in adults. The Abbreviated New Drug Application (ANDA) was reviewed under the expedited provisions of the President’s Emergency Plan for AIDS relief (PEPFAR) in the US.

 

Aurobindo has obtained licence from Gilead for marketing Tenofovir products in 95 developing and least developed countries. So far the Hyderabad-based pharma major has a total of 921 ANDA approvals (66 final and 25 tentative) from the USFDA. crackcrack

Aurobindo Pharma Share Price

1350.00 10.50 (0.78%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×